Cyclin-A2 Antibodies

Cyclin-A2 (CCNA2)

Cyclin which controls both the G1/S and the G2/M transition stages of the cell cycle. Functions through the formation of particular serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2.

The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 through the cell cycle. .

Gene Information

Human
Gene Name:	CCNA2
Uniprot:	P20248
Entrez:	890

Family

Belongs to:
cyclin family

Alternative Names

CCN1CCNAcyclin-A; CCNA; CCNA2; Cyclin A2; Cyclin-A; cyclin-A2

Molecular Weight

Mass (kDA):
48.551 kDA

Genomic Context

Human
Location:	4q27
Sequence:	4; NC_000004.12 (121816444..121823883, complement)

Subcellular Localizations

Nucleus. Cytoplasm. Exclusively nuclear during interphase (PubMed:1312467). Detected in the nucleus and the cytoplasm at prophase (PubMed:1312467). Cytoplasmic when associated with SCAPER (PubMed:17698606).

Diseases

• Malignant Neoplasms
• Neoplasms
• Carcinoma
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Cell Transformation, Neoplastic
• Leukemia
• Retinoblastoma
• Adenocarcinoma
• Liver Carcinoma
• Malignant Paraganglionic Neoplasm
• Hyperplasia
• Malignant Neoplasm Of Lung

• Colorectal Cancer
• Myeloid Leukemia
• Polyploidy
• Colorectal Neoplasms
• Liver Neoplasms
• Lung Neoplasms
• Acute Promyelocytic Leukemia

Interacting Proteins

• AKT1
• CDK2
• CDKN1A
• CDKN1B
• UHRF2

Pathways

• Cell Cycle
• Cell Proliferation
• Mitosis
• S Phase
• Cell Division
• Cell Cycle Arrest
• Regeneration
• Dna Replication
• Cell Growth
• Localization
• Rna Interference
• Spermatogenesis
• Hepatocyte Proliferation

• Liver Regeneration
• Senescence
• Oncogenesis
• Dna Repair
• Pathogenesis
• Neurogenesis
• Meiosis

PTMs

• Phosphorylation
• Methylation
• Sumoylation

• Ubiquitination
• Hydroxylation
• Acetylation

Research Areas

• Cancer
• Cell Biology
• Cell Cycle and Replication
• Cellular Markers
• Core ESC-Like Genes

• Stem Cell Markers
• Tumor Suppressors

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CCNA2

Best Uses Of The CCNA2 Marker

You're in the right place in case you've ever wanted to know how to use a CCNA2 Marker. We'll discuss how to make use of the tool and what it can do for you, and other applications you might be interested in. I hope this article can aid you in deciding which one is the right one for you. In the end, we're all looking for ways to enhance our security capabilities.

Marker CCNA2

The CCNA2 marker might have significant implications for the treatment of breast cancer with immunotherapy. Its importance and function in immune infiltration could make it a useful biomarker for immunotherapy in breast cancer. The study was funded in part by the Natural Science Foundation of China and Zhejiang Medical and Health Science and Technology Planning Project. This article gives a brief overview about the research.

The CCNA2 gene was identified by Coexpression network analysis that weighted the gene as a possible biomarker to be utilized in immunotherapy for breast cancer. The gene is closely related to immune infiltrating cells and could become a target for breast cancer immunotherapy. This discovery needs further study. It is a great moment to study the CCNA2 gene and its potential as a biomarker chemotherapy for breast cancer.

The study was conducted in patients with IPF acute exacerbation. In patients with IPF acute exacerbation CCNA2 was significantly higher in the study group. To verify this finding, CCNA2 gene expression and protein levels were determined by western blot and real-time quantitative reverse transcription-polymerase chain reaction. The findings of this study will help guide further research in the area of lung disease.

Benefits of using the CCNA2 Marker

A CCNA2 Marker is an important marker to detect estrogen receptor positive breast cancer. It plays a role in cell cycle control at the G1/S and G2/M transitions, and may be involved in epithelial-mesenchymal transitions. In addition, to its role in breast cancer, it is also upregulated in other cancers. A CCNA2-related marker can be an important diagnostic tool to detect the earliest signs of disease.

CCNA2 could be a significant biomarker in breast cancer immunotherapy, and its role in the immune system. More research is required to determine the effectiveness of CCNA2 as a biomarker to aid in immunotherapy. The results of this research are supported by the Natural Science Foundation of China, Zhejiang Science & Technology of Analysis and Testing Planning Project, and Taizhou Science & Technology Plan.

Applications of an CCNA2 Marker

The expression of CCNA2 has been linked to immune infiltrates from a variety of cancer, including melanoma , and Sarcoma. The expression of CCNA2 correlates with the expression of immune checkpoints such as CTLA4, CD274, HAVCR2, LAG3, TIGIT, PDCD1, and. Its pan-cancer association has a major impact on understanding the prognostic and immunological role of CCNA2 in various types of cancer.

The expression of CCNA2 is also associated with poor OS as evidenced by Kaplan-Meier and log-rank tests. In addition, it has been demonstrated that upstream miRNAs could predict the expression of CCNA2. This prediction was confirmed by CLIP-Seq studies. Thus, the CCNA2 gene expression could be an indicator biomarker of cancer patients.

CCNA2 is a breast-specific marker that is specific for estrogen receptor positive tumors. It also has a role in cell cycle regulation at the G1/S and G2/M transitions, and may contribute to the epithelial-mesenchymal transition. Many types of cancers have an overexpression of this gene. It isn't known whether CCNA2 expression will aid in the early detection and treatment.

There is a lot of research into the CCNA2 gene. It has been proven to be increased in cancers of the breast, colon, and ovary in comparison to healthy tissues. Other types of cancer, such as prostate cancer, adenocarcinoma as well as the glioblastoma multiforme are also affected by CCNA2.

While CCNA2's role in cancer research isn't fully understood however, it is becoming increasingly important in the field of cancer research. The CCNA2 gene is activated in the acute exacerbation IPF, and a heatmap showing these patterns of gene expression was discovered. CCNA2 gene expression was confirmed by real-time quantitative reverse-transcription-PCR and protein levels were determined using Western blots.